Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd (NSE:PPLPHARMA) (BSE:543635), said on Thursday that it partnered with late-stage biopharma company George Medicines to develop WIDAPLIK, a new drug for treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure.

The US Food and Drug Administration (FDA) approved WIDAPLIK on 6 June 2025.

WIDAPLIK is a single pill combination of three medicines -- telmisartan, amlodipine, and indapamide -- for the treatment of hypertension, developed in three doses (10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg strengths), including two doses that are lower than those currently available in single pill combinations. According to PPS, it is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the established safety profile of its three component antihypertensive medications.

George Medicines and Piramal Pharma Solutions began their collaboration on WIDAPLIK in December 2018, when the formulation was developed at Piramal's Pharmaceutical Development site in Ahmedabad, India.